Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01652079
Title CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

ovarian cancer

peritoneal carcinoma

fallopian tube cancer

Therapies

Bevacizumab + CRLX101

Age Groups: adult
Covered Countries USA


No variant requirements are available.